All In Biotech

Drug Trial Radar · NCT07849894

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in Participants With Mild to Moderate Psoriasis, Single Dose Pharmacokinetics and Safety in Healthy Participants.

A Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Single-Dose, Dose-Escalating Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of UCB0159 in Subjects With Mild to Moderate Psoriasis, and Single-Dose Pharmacokinetics and Safety in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

Jun 23, 2017

Primary completion

Dec 8, 2018

Study completion Dec 8, 2018

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Sep 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and pharmacokinetics of UCB0159 administered in participants with mild to moderate plaque psoriasis and evaluate single dose pharmacokinetics and safety of UCB0159 in healthy participants.

Conditions

  • Mild to Moderate Psoriasis
  • Healthy Volunteers

Interventions

  • UCB0159Drug

    Different dosages will be provided.

  • PlaceboOther

    Placebo will be provided matching UCB0159 to maintain the blinding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events from the Screening Visit through the Safety-Follow Up VisitTime frame: From Screening Visit through Safety Follow-Up Visit (up to Day 85)
  2. Cmax: maximum serum concentration of UCB0159Time frame: Samples will be collected predose (Day -1) and postdose at predefined time points (Day 1 to Day 85)
  3. tmax: time to reach maximum serum concentration of UCB0159Time frame: Samples will be collected predose (Day -1) and postdose at predefined time points (Day 1 to Day 85)
  4. AUC(0-t): Area under the UCB0159 concentration-time curve from time 0 to time t, time of last quantifiable concentrationTime frame: Samples will be collected predose (Day -1) and postdose at predefined time points (Day 1 to Day 85)

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • PS0019 2

    Berlin, Germany

  • PS0019 1

    Harrow, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.